@Article{Hauser2006,
journal="Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology",
issn="1896-6764",
volume="1",
number="1",
year="2006",
title="Review articlePharmacogenomics of antidepressants",
abstract="Genetic factors are believed to play a major role in the variation of treatment response and the incidence of adverse effects of medications. Pharmacogenetics is concerned with the role of genetic factors in predicting drug response and adverse effects. This requires some knowledge of either the drug\’s pharmacokinetic or pharmacodynamic profile so that candidate genes can be studied. Considering the hypothesis for the mechanism of action of antidepressants, most pharmacogenetic studies have concentrated on polymorphisms in genes involved in the serotonergic and noradrenergic system. Many studies have reported an association between the response to SSRI and 5-HTTLPR polymorphism. The aim of pharmacogenomic is to study the relationship between whole genome factors including the expressed transcriptome and proteome and drug response. It is hoped that pharmacogenomic studies will lead to the prediction of response to antidepressants and reduction of adverse effects.",
author="Hauser, Joanna",
pages="43--48",
url="https://www.termedia.pl/Review-article-Pharmacogenomics-of-antidepressants,46,7119,1,1.html"
}